Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01515137 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 47 | University of PittsburghOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05766150 | Oral Microbioma and Oral Malignant Disease | unknown | — | 300 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT01590355 | A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)(ORATOR) | unknown | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Mar 8, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03518671 | Building a Renewed ImaGe After Head & Neck Cancer Treatment(BRIGHT) | completed | N/A | 11 | Medical University of South CarolinaOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02707588 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC(PembroRad) | completed | Phase 2 | 133 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04929067 | Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial | unknown | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04359199 | QUantitative Assessment of Swallowing After Radiation (QUASAR)(QUASAR) | unknown | — | 42 | Loren Mell, MDOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05578170 | Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma(PROBES) | unknown | — | 47 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02158234 | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 2 | 30 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT03032250 | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer | completed | N/A | 35 | Wake Forest University Health SciencesOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | terminated | N/A | 2 | Aethlon Medical Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck(ERM-PT-HNSCC) | terminated | — | 12 | Leiden University Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03129061 | Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 | 15 | CellSight Technologies, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02764593 | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | completed | Phase 1 | 40 | RTOG Foundation, Inc.OTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT03620123 | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck(OPTIM) | completed | Phase 2 | 54 | AIO-Studien-gGmbHOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT03405142 | Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | completed | Phase 2 | 3 | Eben RosenthalOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05143268 | Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma(ACP-HN) | unknown | — | 90 | Lorenzo LiviOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05611463 | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE) | unknown | Phase 2 | 25 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05611515 | Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies(SUPRA-QoL) | recruiting | — | 108 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03817307 | Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma(USPIO-NECK) | unknown | N/A | 25 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04803331 | SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification(MAG-NODE) | unknown | N/A | 10 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 46 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05024383 | Dissecting the Heterogeneity of Oral Cancer Pain | unknown | N/A | 80 | NYU College of DentistryOTHER | 1 | Sep 28, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2023source: clinicaltrials